NEWS
Cytokinetics Stock Scores RS Rating Jump To 83
2025-09-29
Cytokinetics stock cleared that benchmark Monday, with a jump from 78 to 83 Monday. IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes. Cytokinetics stock has climbed more than 5% past a 47.90 entry in a first-stage consolidation, meaning it's now out of a proper buy range.
Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025
2025-09-29
Additional Data from MAPLE-HCM Show Aficamten Significantly Improves Measures of Maximaland Submaximal Exercise Capacity and Recovery Compared to Metoprolol 96-Week Analyses from FOREST-HCM SupportLong-Term Efficacy and Tolerability of Aficamten in Patients with Non-Obstructive HCM SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data related to aficamten were presented in a Late Breaking Clinical Research s
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program
2025-09-24
Program to Provide Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is November 3rd, 2025 SOUTH SAN FRANCISCO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the eighth annual Cytokinetics Communications Grant Program. The program will award five grants to patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM) a
Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
2025-09-23
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to present a corporate update at the Stifel 2025 Virtual Cardiometabolic Forum on Tuesday, September 30, 2025 at 10:00 AM Eastern Time. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-09-18
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2025 it granted stock options to purchase an aggregate of 39,790 shares of common stock and 26,822 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 11 employees, whose employment commenced in August and September 2025 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the
Cytokinetics (CYTK) Drops on $650-Million Debt Issuance
2025-09-18
We recently published 10 Big Names Investors Are Dumping. Cytokinetics, Inc. (NASDAQ:CYTK) is one of the worst performers on Wednesday. Shares of Cytokinetics dropped by 4.42 percent on Wednesday to end at $47.56 apiece after upsizing its senior convertible notes issuance to $650 million. In a statement, Cytokinetics, Inc. (NASDAQ:CYTK) said it aimed to raise […]
Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025
2025-09-18
Long-Term Data from FOREST-HCM in Non-Obstructive HCM and Results from Prespecified Analysis of MAPLE-HCM to be Presented in Late-Breaking Clinical Research Session SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming presentations, including two Late Breaking Clinical Research presentations and one poster presentation, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025 taking place in
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes
2025-09-17
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of the offering
Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes
2025-09-16
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”
Cytokinetics (CYTK): Is the Current Market Valuation Overlooking the Company’s Long-Term Potential?
2025-09-11
If you have been keeping an eye on Cytokinetics (CYTK), you might be wondering what the latest market activity means for your portfolio or watchlist. There has not been a single headline-grabbing event sparking this move, but the action around the stock is more than enough to grab investor attention. Sometimes, shifts happen quietly in the background, raising good questions about whether the market is catching onto something insiders see, or if it is just business as usual. Looking at the...
